Processa Pharmaceuticals, Inc.
- PCSA
- NASDAQ
- Biotechnology
- Clinical-Stage Biopharma
$1.69
Today +0.60%Quote Oct 16, 2026, 08:00 PM UTC
−11.05%over the last month
Max drawdown −31.1%From 1-month high −13.8%3 months −23.9%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Market value
$4.7M
Quote Oct 16
Next earnings
Oct 29
Expected, not confirmed
Analyst target
$225.00
+13213.6% from here
Floor
$1.67
1.2% below price
Where the price sits
No analyst target range for this stock.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about PCSAPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days freeWhere the money comes from
No revenue split by segment on file.
Industry
Biotechnology
Employees
12
Founded
2011